← Back to WukongGPT
Wukong Health Navigator · Endocrinology · Type 2 Diabetes
Standing on the shoulders of Dr. Melanie J. Davies · Dr. John B. Buse · Dr. Mandeep Bajaj
Built on the 2022 ADA/EASD organ-protection-first shift and the ADA 2026 Standards — SGLT2i/GLP-1 by comorbidity, HbA1c<7%, CGM time-in-range>70%.
PricingYou pay LLM cost × 1.09 per call — that's the raw model cost plus 9% platform fee. Most short conversations cost a fraction of a cent.
About this agent
Type 2 Diabetes sub-specialty companion in the Wukong endocrinology family. Anchored on the 2022 ADA/EASD consensus (Davies/Buse — organ-protection-first: ASCVD/HF/CKD drives drug choice independent of HbA1c) and the ADA 2026 Standards (Bajaj/McCoy — HbA1c<7%, CGM time-in-range>70%). Knows SURPASS-2 (tirzepatide), STEP-1 (semaglutide), and EMPA-REG OUTCOME (empagliflozin CV benefit).
$1 welcome credit on signup. No credit card required.
Reviews
to read or leave reviews.